AccurKardia develops the AccurECG™ analysis system, an FDA-cleared software that automates the interpretation of ECGs to enhance diagnostic accuracy. By leveraging both visible and hidden signals within ECG data, the platform extends ECG applications beyond traditional uses, improving patient outcomes and enabling better management of various health conditions.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional electrocardiogram (ECG) interpretation can be time-consuming and may not always capture subtle indicators of underlying health conditions. Relying solely on visible signals within ECG data may limit the full diagnostic potential of this widely available tool.
Solution
AccurKardia's AccurECG™ analysis system is an FDA-cleared software designed to automate and enhance ECG interpretation by leveraging both visible and hidden signals within ECG data. The platform aims to transform ECGs into a more powerful diagnostic tool and broad biomarker, extending their use beyond traditional capabilities. By streamlining the interpretation process and uncovering previously unseen insights, AccurKardia seeks to improve patient outcomes and enable better management of various health conditions. The system is intended to be used as an advisory tool in conjunction with a physician's expertise and other diagnostic information.
Target Audience
The primary users are qualified healthcare professionals who interpret ECGs and seek to enhance diagnostic accuracy.
Features
- Automated ECG interpretation software
- FDA-cleared AccurECG™ analysis system
- Analysis of both visible and hidden signals within ECG data
- Aims to extend ECG applications beyond traditional uses